ImmuCell Reports Q3 2026 Profitability and 46% Revenue Growth
ImmuCell Corporation (ICCC) delivered strong third-quarter 2026 financial results, transitioning from a net loss in the previous year to a net income of $953,000. The company reported revenue of $8 million, marking a 46% year-over-year increase driven by higher pricing and improved sales volumes. International sales saw an exceptional surge of 573%, primarily due to clearing back orders in the Canadian market. Operational improvements were evident through increased manufacturing yields and a gross margin expansion to 44.2%. The company's cash position significantly strengthened, ending the quarter with $7.9 million in cash and cash equivalents. While ImmuCell is investing in capacity expansion for freeze-drying and liquids projects, management noted potential supply chain headwinds due to rising colostrum sourcing costs.
Topics: EPS Gross Margin International Sales Net Income Revenue Growth